David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total transaction of $124,770.75. Following the transaction, the insider directly owned 871,737 shares in the company, valued at $8,760,956.85. This represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

David Kirn also recently made the following trade(s):

• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.87, for a total transaction of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $19,258.44.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $10.28 on Thursday. The company has a market capitalization of $537.44 million, a price-to-earnings ratio of -4.00 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a 52-week low of $5.33 and a 52-week high of $14.00. The company has a 50-day simple moving average of $10.67 and a two-hundred day simple moving average of $9.71.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. On average, sell-side analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. Finally, The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $30.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Exome Asset Management LLC bought a new position in 4D Molecular Therapeutics during the first quarter worth about $1,216,000. Evergreen Quality Fund GP Ltd. bought a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $7,136,000. Simplify Asset Management Inc. purchased a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at approximately $656,000. Baker BROS. Advisors LP purchased a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at approximately $3,568,000. Finally, Janus Henderson Group PLC boosted its holdings in 4D Molecular Therapeutics by 13.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after buying an additional 611,276 shares during the period. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.